Haleos Labs Limited announced its standalone and consolidated financial results for the quarter and year ended March 31, 2026, during its 97th board meeting held on May 29, 2026. The company also recommended a dividend of ₹1.50 per equity share (15%) for the year 2025-26, subject to shareholder approval at the upcoming 20th Annual General Meeting. Additionally, the board approved the appointment of M/s. Suryanarayana & Suresh as Statutory Auditors for five years and noted the resignation of Independent Director Mrs. Sundaramma Patibandla.

Haleos Labs Limited, formerly known as SMS Lifesciences India Limited, is a Hyderabad-based company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and their intermediates. The company operates as a single reportable business segment and has a subsidiary named Mahi Drugs Private Limited. Recently, the company has been active in restructuring its board committees following the resignation of an independent director and has reaffirmed its compliance with the new labor codes effective from November 21, 2025.